Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIn clinical trials, adults taking Wegovy (semaglutide 2.4 mg) lost an average of around 15% of their body weight over 68 weeks, according to the STEP 1 trial published in the New England Journal of Medicine. Real-world results vary — but if you're also trying to work out what the treatment costs in the UK, both questions matter before you start. Wegovy is a prescription-only medicine; a clinician has to assess your suitability before any supply is legal.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial is the number most often quoted: roughly 15% average weight loss at 68 weeks on semaglutide 2.4 mg. That figure comes from 1,961 adults with obesity or overweight and at least one weight-related condition, compared against a placebo group. It is a meaningful result. But averages hide a wide spread (some participants lost considerably more, others less) and the trial was run alongside structured diet and lifestyle support, which matters for how the medicine performs.
If you want to look at how much weight people have actually lost on Wegovy across the trial data, our breakdown covers the full range in more detail. The short version: individual results depend on starting weight, adherence, dose reached, and lifestyle changes alongside treatment, and our guide to how much weight can realistically be lost on Wegovy sets out what the evidence says for different starting points. A prescriber can give you a realistic picture of what to expect for your situation, which is exactly why the consultation matters before anything else.
The NICE appraisal of semaglutide for weight management (TA875) recommends it within specialist services for adults who meet specific BMI and comorbidity thresholds. Private treatment through a regulated pharmacy is a separate, legal route for those who don't meet NHS criteria or prefer not to wait.
Since Eli Lilly's price increase in September 2025 reshaped the market, Wegovy's private pricing has landed in a comparable range to tirzepatide at many providers. Reported private prices for semaglutide in the UK typically run from around £149 to £375 per month depending on the dose and the pharmacy, those figures are widely cited and should be treated as a rough guide, not a quote. Your actual monthly cost changes as your dose is titrated upward by your prescriber over the first several months of treatment.
What those headline figures often exclude: the initial consultation fee (which some providers charge separately), any follow-up prescription fees, delivery costs, and aftercare support between doses. Add those up across a year and the gap between a low advertised price and the real monthly outlay can be significant. If you are looking to reduce the cost, it is also worth checking whether a Wegovy voucher or savings programme applies to your situation before you commit. Our Wegovy pricing page sets out the full cost picture without the small print.
nume prices one thing: treatment that includes everything. One transparent cost covers the consultation, the prescription, the medicine itself, and free next-working-day delivery. There are no separate line items. We are not the cheapest option on the market, and that is a deliberate choice, not an oversight. More about how we operate is on our about page if you'd like the background before you decide.
Wegovy is a prescription-only medicine. That means the only legal route to it is a valid prescription following a genuine clinical assessment, not a quick online form that nobody reads, not a seller on social media, not a listing that seems suspiciously far below the going rate. The MHRA has been clear on this: fake and illegally traded weight-loss pens are a real problem in the UK, with large seizures of counterfeit stock reported through 2024 and 2025. The MHRA's Yellow Card scheme lets you report any suspect seller directly.
A clinical review before every order is what keeps treatment safe. At nume, every consultation (including repeats and dose reviews) is read by a real prescriber, not processed by software. Your pen travels from our GPhC-registered pharmacy (registration 9012878) and arrives with DPD tracking the next working day. Kept in the fridge door between doses, it stays stable and ready. That combination of verified supply chain and ongoing clinical oversight is what you're paying for, and it's what price comparisons tend not to show.
If you're trying to understand whether Wegovy is the right treatment for your situation, or want to know how much you have to weigh to get Wegovy and whether your current weight meets the threshold, the free consultation is the right place to start. Current treatment options and pricing are shown on our treatment page. You can also explore our weight-loss overview if you want to compare the options before committing to anything.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.